secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2026-08-04T11:49:13+00:00
Accession:  0001628280-26-052170
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma Q2 revenue $71.3M; RM-718 shows -11.6% BMI reduction in HO
------------------------------------------------------------------------

- Q2 2026 IMCIVREE revenue $71.3M, up 19% sequentially; U.S. revenue $51.0M (+38% QoQ).
- Over 400 patient start forms for IMCIVREE in acquired HO since FDA approval in March 2026.
- RM-718 Phase 2: -11.6% mean BMI reduction at 16 weeks (n=7) in acquired HO, comparable to setmelanotide.
- Net loss $(50.4)M ($(0.73)/share) vs $(48.0)M ($(0.75)/share) in Q2 2025.
- Cash $330.9M; FY 2026 Non-GAAP OpEx guidance $363M-$397M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000162828026052170/0001628280-26-052170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000162828026052170/rytm-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-052170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer